Telesis Bio Inc.
DelistedCIK 1850079fmd_12SJQ134EB7MXHHTDGJRQ53C74Manufacturing · Laboratory Analytical InstrumentsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2024, 19 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | 7 | 11 | 27 | 28 |
| Cost of revenue | 3 | 7 | 12 | 11 |
| Gross profit | 4 | 4 | 16 | 17 |
| Provision for credit losses | – | – | 0 | 1 |
| Research and development | 9 | 14 | 23 | 17 |
| Selling, general and administrative | 11 | 25 | 39 | 35 |
| Total operating expenses | 20 | 40 | 62 | 63 |
| Operating income | (16) | (35) | (46) | (47) |
| Interest expense | – | – | 2 | 3 |
| Interest and investment income | – | – | 1 | 2 |
| Other non-operating income (expense) | (2) | (4) | (2) | (1) |
| Income before taxes | (18) | (39) | (48) | (48) |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (18) | (39) | (48) | (48) |
| Net income | (18) | (39) | (48) | (48) |
| Net income to common shareholders | (18) | (39) | (48) | (49) |